Power of rare diseases: Found in translation

Science Translational Medicine

Volumn 5, Issue 201, 2013, Pages

  Fishman, Mark C ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CANAKINUMAB; EVEROLIMUS; INTERLEUKIN 17; INTERLEUKIN 1BETA; LCI 699; MAMMALIAN TARGET OF RAPAMYCIN; MAVOGLURANT; SECUKINUMAB; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ASTROCYTOMA; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CROHN DISEASE; CUSHING DISEASE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDICATION; EXPLORATORY RESEARCH; FMR1 GENE; FRAGILE X SYNDROME; GENE; GENETICS; HUMAN; HYPERALDOSTERONISM; MUCKLE WELLS SYNDROME; NALP3 GENE; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RARE DISEASE; REVIEW; RHEUMATOID ARTHRITIS; STOMATITIS; THEORY; TUBEROUS SCLEROSIS;

ADULT; CLINICAL TRIALS AS TOPIC; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DRUG DESIGN; DRUG DISCOVERY; FEMALE; HUMANS; PATIENT SELECTION; RARE DISEASES; RESEARCH DESIGN; TRANSLATIONAL MEDICAL RESEARCH; TUBEROUS SCLEROSIS;

EID: 84884153333     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006800     Document Type: Review

References (21)

1. J. L. Fox, FDA moves on breakthrough therapies. Nat. Biotechnol. 31, 374 (2013).
2. Y. Ogura, F. S. Sutterwala, R. A. Flavell, The inflammasome: First line of the immune response to cell stress. Cell 126, 659-662 (2006).
3. P. N. Hawkins, H. J. Lachmann, M. F. McDermott, Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348, 2583-2584 (2003).
4. F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, J. Tschopp, Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
5. D. A. Krueger, M. M. Care, K. Holland, K. Agricola, C. Tudor, P. Mangeshkar, K. A. Wilson, A. Byars, T. Sahmoud, D. N. Franz, Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801-1811 (2010).
6. J. J. Bissler, J. C. Kingswood, E. Radzikowska, B. A. Zonnenberg, M. Frost, E. Belousova, M. Sauter, N. Nonomura, S. Brakemeier, P. J. de Vries, V. H. Whittemore, D. Chen, T. Sahmoud, G. Shah, J. Lincy, D. Lebwohl, K. Budde, Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381, 817-824 (2013).
7. J. Baselga, M. Campone, M. Piccart, H. A. Burris, 3rd, H. S. Rugo, T. Sahmoud, S. Noguchi, M. Gnant, K. I. Pritchard, F. Lebrun, J. T. Beck, Y. Ito, D. Yardley, I. Deleu, A. Perez, T. Bachelot, L. Vittori, Z. Xu, P. Mukhopadhyay, D. Lebwohl, G. N. Hortobagyi, Everolimus in postmenopausal hormone-receptor- positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2012).
8. E. Bettelli, M. Oukka, V. K. Kuchroo, T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8, 345-350 (2007).
9. W. Hueber, D. D. Patel, T. Dryja, A. M. Wright, I. Koroleva, G. Bruin, C. Antoni, Z. Draelos, M. H. Gold, P. Durez, P. P. Tak, J. J. Gomez-Reino, C. S. Foster, R. Y. Kim, C. M. Samson, N. S. Falk, D. S. Chu, D. Callanan, Q. D. Nguyen, K. Rose, A. Haider, F. Di Padova, Psoriasis Study Group, Rheumatoid Arthritis Study Group, Uveitis Study Group, Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52ra72 (2010).
10. W. Hueber, B. E. Sands, S. Lewitzky, M. Vandemeulebroecke, W. Reinisch, P. D. R. Higgins, J. Wehkamp, B. G. Feagan, M. D. Yao, M. Karczewski, J. Karczewski, N. Pezous, S. Bek, G. Bruin, B. Mellgard, C. Berger, M. Londei, A. P. Bertolino, G. Tougas, S. P. L. Travis, Secukinumab in Crohn's Disease Study Group, Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693-1700 (2012).
11. M. F. Bear, K. M. Huber, S. T. Warren, The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377 (2004).
12. S. Jacquemont, A. Curie, V. des Portes, M. G. Torrioli, E. Berry-Kravis, R. J. Hagerman, F. J. Ramos, K. Cornish, Y. He, C. Paulding, G. Neri, F. Chen, N. Hadjikhani, D. Martinet, J. Meyer, J. S. Beckmann, K. Delange, A. Brun, G. Bussy, F. Gasparini, T. Hilse, A. Floesser, J. Branson, G. Bilbe, D. Johns, B. Gomez-Mancilla, Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with diff erential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 3, ra1 (2011).
13. E. L. Korn, L. M. McShane, B. Freidlin, Statistical challenges in the evaluation of treatments for small patient populations. Sci. Transl. Med. 5, sr3 (2013).
14. J. Orloff, F. Douglas, J. Pinheiro, S. Levinson, M. Branson, P. Chaturvedi, E. Ette, P. Gallo, G. Hirsch, C. Mehta, N. Patel, S. Sabir, S. Springs, D. Stanski, M. R. Evers, E. Fleming, N. Singh, T. Tramontin, H. Golub, The future of drug development: Advancing clinical trial design. Nat. Rev. Drug Discov. 8, 949-957 (2009).
15. J. Lind, A treatise of the scurvy. In three parts. Containing an inquiry into the nature, causes and cure, of that disease. Together with a critical and chronological view of what has been published on the subject (Sands, Murray, and Cochran for A. Kincaid and A. Donaldson, Edinburgh, 1753).
16. E. I. Chazov, L. S. Matveeva, A. V. Mazaev, K. E. Sargin, G. V. Sadovskaia, M. I. Ruda, Intracoronary administration of fibrinolysin in acute myocardial infarct. Ter. Arkh. 48, 8-19 (1976).
17. A. Gilman, The initial clinical trial of nitrogen mustard. Am. J. Surg. 105, 574-578 (1963).
18. M. Rask-Andersen, M. S. Almén, H. B. Schiöth, Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10, 579-590 (2011).
19. A. Mullard, 2012 FDA drug approvals. Nat. Rev. Drug Discov. 12, 87-90 (2013).
20. M. E. Bunnage, Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 7, 335-339 (2011).
21. M. C. Fishman, Power of rare diseases: Found in translation. Sci. Transl. Med. 5, 201ps11 (2013).